NanoString Technologies

NanoString Technologies, Inc. engages in the development and commercialization of instruments and services for profiling of genes and proteins from tissue sample. It offers the GeoMx Digital Spatial Profiler, nCounter Analysis System product platforms, GeoMx Assays, nCounter Panels & Assays and CosMx Spatial Molecular. The company was founded by Amber Ratcliffe, Krassen Dimitrov, and Dwayne Dunaway on June, 2003 and is headquartered in Seattle, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

NanoString Technologies reports robust Q4 revenue and optimistic 2023 outlook

NanoString Technologies showcased strong Q4 2022 performance with revenue exceeding guidance and a positive outlook for 2023.
While facing challenges such as expected EBITDA losses and nCounter revenue decline, NanoString is leveraging opportunities in spatial biology and customer synergies.
The company's strengths lie in market-leading technology, positive customer feedback on CosMx instruments, and a cash-generating nCounter business.
Overall, NanoString's strategic focus on spatial biology and operational improvements position it for continued growth and innovation.

NanoString Technologies surpasses Q1 revenue targets, CosMx shines

NanoString Technologies had a strong Q1 2023, exceeding revenue guidance and raising full-year expectations.
Positive customer feedback and competitive positioning of CosMx in the spatial imager category are key strengths.
Challenges include EBITDA loss, capacity constraints, and shifts in product demand.
Opportunities lie in achieving cash flow breakeven, product growth, and market dominance with CosMx.

NanoString Technologies reports record Q2 revenue and strategic growth plans

NanoString Technologies delivered strong Q2 results, exceeding revenue guidance and showcasing growth in spatial biology.
The company's strategic objectives for 2023 focus on market expansion and product innovation, supported by a commitment to operational efficiency.
While facing challenges such as ongoing litigation and financial discussions, NanoString remains optimistic about its growth prospects and balance sheet strengthening.

NanoString Technologies achieves record revenue, eyes growth opportunities in 2024

NanoString Technologies reported strong revenue growth and cost reduction in Q3 2023.
Focus on spatial biology market penetration and new product offerings to drive future growth.
Legal challenges in Europe and backlog delays pose challenges to be addressed.
Improved gross margins and lower expenses expected to enhance profitability by 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.

SEATTLE--(BUSINESS WIRE)--NanoString announces pricing of upsized public stock offering.

NanoString Technologies Announces Pricing of Upsized Public Offering of $200 Million of Common Stock

SEATTLE--(BUSINESS WIRE)--NanoString Announces Commencement of Public Offering of Common Stock

NanoString Technologies Announces Commencement of Public Offering of Common Stock

SEATTLE--(BUSINESS WIRE)--NanoString announces preliminary operating results for third quarter of FY20.

NanoString Technologies Provides Preliminary Financial and Operational Highlights for Third Quarter 2020

SEATTLE--(BUSINESS WIRE)--NanoString announces date of third quarter earnings call.

NanoString to Release Third Quarter 2020 Operating Results and Host Conference Call on Monday, November 9, 2020

SEATTLE--(BUSINESS WIRE)--NanoString announces expanded access to next-gen sequencing readout for GeoMx DSP.

NanoString Launches Whole Transcriptome Atlas under GeoMx Technology Access Program and Names First GeoMx Premier Access Sites

SEATTLE--(BUSINESS WIRE)--NanoString to webcast fireside chat presentation from the Morgan Stanley Global Healthcare Conference.

NanoString to Present at the 18th Annual Morgan Stanley Global Healthcare Conference

SEATTLE--(BUSINESS WIRE)-- #COVID--NanoString announces GeoMx Translational Leadership Network and Spatial Biology Summit.

NanoString Announces New GeoMx COVID-19 Consortium, Part of the GeoMx Translational Leadership Network

SEATTLE--(BUSINESS WIRE)--NanoString to participate in the Baird Global Healthcare Conference.

NanoString to Present at the 2020 Baird Global Healthcare Conference

NanoString Technologies, Inc. (NSTG) CEO Brad Gray on Q2 2020 Results - Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString Technologies Releases Operating Results for Second Quarter of 2020

NanoString Technologies Releases Operating Results for Second Quarter of 2020

SEATTLE & MINNEAPOLIS--(BUSINESS WIRE)--NanoString Expands RNAscope Partnership with Bio-Techne's ACD Division.

NanoString and Bio-Techne Announce Offering of RNAscope Reagents Validated for Use With the GeoMx Digital Spatial Profiler

NanoString Technologies (NSTG) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

NanoString Technologies (NSTG) Surges: Stock Moves 10.3% Higher

NanoString Technologies, Inc. (NSTG) CEO Brad Gray on Q1 2020 Results - Earnings Call Transcript

NanoString Technologies (NSTG) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why NanoString Technologies (NSTG) Stock Might be a Great Pick

As of late, it has definitely been a great time to be an investor in NanoString Technologies.

Will NanoString Technologies Continue to Surge Higher?

NanoString Technologies, Inc. (NSTG) CEO Brad Gray on Q4 2019 Results - Earnings Call Transcript

Cara Therapeutics

Portola Pharmaceuticals

These three small companies have the potential to make you a lot of money.

3 Small-Cap Healthcare Stocks With Large-Cap Potential

NanoString Technologies' (NSTG) CEO Brad Gray on Q3 2019 Results - Earnings Call Transcript

NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate NanoString Technologies (NSTG) to Report a Decline in Earnings: What to Look Out for

SEATTLE, Aug.  28, 2019  (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at the 2019 Morgan Stanley Global Healthcare Conference in New York City.

NanoString to Present at the 2019 Morgan Stanley Global Healthcare Conference

SEATTLE, Aug.  19, 2019  (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at the Baird 2019 Global Healthcare Conference in New York City.

NanoString to Present at the Baird 2019 Global Healthcare Conference

President and CEO of Nanostring Technologies Inc (30-Year Financial, Insider Trades) R Bradley Gray (insider trades) sold 40,000 shares of NSTG on 08/12/2019 at an average price of $24.84 a share.

Nanostring Technologies Inc (NSTG) President and CEO R Bradley Gray Sold $993,600 of Shares

CFO of Nanostring Technologies Inc (30-Year Financial, Insider Trades) K Thomas Bailey (insider trades) sold 35,625 shares of NSTG on 08/06/2019 at an average price of $25.24 a share.

Nanostring Technologies Inc (NSTG) CFO K Thomas Bailey Sold $899,175 of Shares

All eyes were on a new instrument launch, which got off to a strong start judging from pre-orders.

NanoString Technologies Delivers 21% Revenue Growth in Q2

NanoString Technologies, Inc. (NSTG) CEO Brad Gray on Q2 2019 Results - Earnings Call Transcript

News for NanoString Technologies Stock (NSTG)